vTv Therapeutics Inc expected to post a loss of 4 cents a share - Earnings Preview
Brief: Medpace Investors Reports 5.16% Passive Stake Of Class A Common Stock In vTv Therapeutics
vTv Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: vTv Therapeutics Reports Net Loss Of $0.04 Per Basic Share
vTv Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview
vTv Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview
Brief: Vtv Therapeutics Announces Paul Sekhri As New President And Chief Executive Officer
U.S. STOCKS ON THE MOVE-ToughBuilt Industries Inc, Koss Corp, Centene Corp
U.S. STOCKS ON THE MOVE-Lakeland Financial, World Wrestling Entertainment, Bank of Marin
U.S. STOCKS ON THE MOVE-Soligenix, Veru, American Express
vTv Therapeutics up on $10 mln investment by CinRx Pharma
Brief: Vtv Therapeutics Announces Investment By Cinrx Pharma
U.S. STOCKS ON THE MOVE-Lithium stocks, 3M, TG Therapeutics
U.S. STOCKS ON THE MOVE-Salesforce, Enochian BioSciences, Spark Networks
Brief: vTv Therapeutics Reports Collaboration and License Agreement with affiliates of G42 Healthcare
vTv Therapeutics surges on deal for diabetes therapy development
Brief: vTv Therapeutics Announces 2022 First Quarter Financial Results
Brief: VTV Therapeutics Inc - QTRLY Net Loss Per Share Of $0.10
vTv Therapeutics Inc expected to post a loss of 8 cents a share - Earnings Preview